U.S. markets open in 1 hour 39 minutes
  • S&P Futures

    -14.25 (-0.28%)
  • Dow Futures

    -121.00 (-0.31%)
  • Nasdaq Futures

    -47.25 (-0.26%)
  • Russell 2000 Futures

    +5.30 (+0.26%)
  • Crude Oil

    +0.27 (+0.34%)
  • Gold

    -4.70 (-0.23%)
  • Silver

    -0.07 (-0.31%)

    -0.0009 (-0.09%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.24 (+1.73%)

    -0.0015 (-0.12%)

    -0.6030 (-0.40%)
  • Bitcoin USD

    +3,083.38 (+5.19%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    +24.91 (+0.33%)
  • Nikkei 225

    -41.84 (-0.11%)

Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer

Exelixis, Inc. EXEL announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking approval for its lead drug, Cabometyx (cabozantinib), in combination with Bristol Myers Squibb’s BMY immune-checkpoint inhibitor Opdivo (nivolumab) for previously untreated renal cell carcinoma (RCC). RCC is the most common type of kidney cancer in adults.

Shares of the company have rallied 22.8% year to date compared with a flat movement by the industry.

Notably, Cabometyx, a tablet formulation of cabozantinib, is already approved in the United States for the treatment of patients with advanced RCC. The drug is also approved for hepatocellular carcinoma (HCC) patients who have been previously treated with Bayer AG’s BAYRY Nexavar (sorafenib) in Europe and the United States.

The sNDA is supported by data from the phase III pivotal CheckMate-9ER study, which evaluated Cabometyx   plus Opdivo versus Pfizer’s PFE Sutent (sunitinib) in previously untreated patients with advanced or metastatic disease. The study met theprimary endpoint by showing that treatment with Cabometyx+ Opdivo results insignificant improvement in progression-free survival (PFS) compared with Sutent. Two secondary endpoints of overall survival and the objective response ratewere also achieved.

If approved, the combination of Cabometyx and Opdivo will be an important, new first-line treatment regimen for RCC patients who need additional therapeutic options that extend survival.

Cabometyx generated sales of $362.8 million in the first half of 2020, representing about 74.6% of total revenues. The uptake of the drug, since its approval (April 2016), has been strong. The company’s efforts to develop Cabometyx for various other indications are also encouraging. Label expansion of the drug for additional indications should further boost sales.


Exelixis, Inc. Price

Exelixis, Inc. Price
Exelixis, Inc. Price

Exelixis, Inc. price | Exelixis, Inc. Quote

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research